Orchestra Biomed Holdings

OBIO · NASDAQ

$5.82+$0.17 (+3.01%)TodayMarket closed · Oct 21, 5:03 AM ET

Prev close $5.65

OBIO analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 9 analysts

Average $12.68 (+117.8% upside)

Low: $9.09
Now: $5.82
High: $21.00

Upgrades and downgrades

The latest rating actions, newest first

OBIO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B. Riley Securities	Sep 15, 2026	Maintains	Buy	$10.00 → $11.00	30%
BTIG	Sep 10, 2026	Upgrade	Neutral → Buy	$10.00	56%
Piper Sandler	Aug 11, 2026	Maintains	Overweight	$9.00 → $10.00	43%
B. Riley Securities	May 19, 2026	Maintains	Buy	$12.00 → $10.00	48%
HC Wainwright & Co.	May 14, 2026	Maintains	Buy	$10.00	40%
Barclays	May 13, 2026	Maintains	Overweight	$12.00 → $13.00	57%
Chardan Capital	Mar 12, 2026	Maintains	Buy	$20.00	38%
Barclays	Jan 9, 2026	Maintains	Overweight	$11.00 → $12.00	57%
TD Cowen	Dec 10, 2025	Initiates	Buy	$15.00	48%
Chardan Capital	Nov 13, 2025	Maintains	Buy	$20.00	38%

The case for and against

Updated Oct 17, 2026

Bull case

Orchestra BioMed Hldgs is attractive because its two clinical-stage programs, BACKBEAT and Virtue SAB, target very large underserved cardiovascular markets while using a capital-light partnership model that can convert R&D expertise into high-margin commercialization. The BACKBEAT trial is nearing completion of enrollment by the end of 3Q26, has a 316-patient design with 284 evaluable randomized subjects, and benefits from FDA Breakthrough Device designations that could expand the U.S. addressable AVIM population to 7.7M. Financially, the company ended Q2 with $110M in cash and equivalents, received $35M of strategic capital, and expects runway into 4Q27, supporting multiple near-term catalysts and improved opex leverage as trials mature.

Bear case

Orchestra BioMed Hldgs is a highly speculative MedTech story because its valuation depends on uncertain commercialization of AVIM Therapy and Virtue SAB, with Virtue SAB also requiring a commercial partner. The company’s outlook is pressured by cash burn, possible additional funding needs, and regulatory and trial-enrollment risks, while the analysis assigns only 65% approval odds to AVIM Therapy and 40% to Virtue SAB. Even with $129.4M cash, $14.3M debt, and $20M preferred stock, the business remains exposed to dilution and partner execution risk, making fundamental visibility weak.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.